These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

297 related items for PubMed ID: 20336784

  • 21. Cyclin-dependent kinase 2 is an ideal target for ovary tumors with elevated cyclin E1 expression.
    Yang L, Fang D, Chen H, Lu Y, Dong Z, Ding HF, Jing Q, Su SB, Huang S.
    Oncotarget; 2015 Aug 28; 6(25):20801-12. PubMed ID: 26204491
    [Abstract] [Full Text] [Related]

  • 22. Biological and clinical significance of NAC1 expression in cervical carcinomas: a comparative study between squamous cell carcinomas and adenocarcinomas/adenosquamous carcinomas.
    Yeasmin S, Nakayama K, Rahman MT, Rahman M, Ishikawa M, Katagiri A, Iida K, Nakayama N, Otuski Y, Kobayashi H, Nakayama S, Miyazaki K.
    Hum Pathol; 2012 Apr 28; 43(4):506-19. PubMed ID: 21889186
    [Abstract] [Full Text] [Related]

  • 23. c-myc and chromosome 8 centromere studies of ovarian cancer by interphase FISH.
    Wang ZR, Liu W, Smith ST, Parrish RS, Young SR.
    Exp Mol Pathol; 1999 Jun 28; 66(2):140-8. PubMed ID: 10409442
    [Abstract] [Full Text] [Related]

  • 24. Comprehensive analysis of 20q13 genes in ovarian cancer identifies ADRM1 as amplification target.
    Fejzo MS, Dering J, Ginther C, Anderson L, Ramos L, Walsh C, Karlan B, Slamon DJ.
    Genes Chromosomes Cancer; 2008 Oct 28; 47(10):873-83. PubMed ID: 18615678
    [Abstract] [Full Text] [Related]

  • 25. Expression and amplification of eIF-5A2 in human epithelial ovarian tumors and overexpression of EIF-5A2 is a new independent predictor of outcome in patients with ovarian carcinoma.
    Yang GF, Xie D, Liu JH, Luo JH, Li LJ, Hua WF, Wu HM, Kung HF, Zeng YX, Guan XY.
    Gynecol Oncol; 2009 Feb 28; 112(2):314-8. PubMed ID: 19054548
    [Abstract] [Full Text] [Related]

  • 26. Expression analysis and prognostic significance of the SRA1 gene, in ovarian cancer.
    Leoutsakou T, Talieri M, Scorilas A.
    Biochem Biophys Res Commun; 2006 Jun 02; 344(2):667-74. PubMed ID: 16631123
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas.
    Chung CH, Ely K, McGavran L, Varella-Garcia M, Parker J, Parker N, Jarrett C, Carter J, Murphy BA, Netterville J, Burkey BB, Sinard R, Cmelak A, Levy S, Yarbrough WG, Slebos RJ, Hirsch FR.
    J Clin Oncol; 2006 Sep 01; 24(25):4170-6. PubMed ID: 16943533
    [Abstract] [Full Text] [Related]

  • 30. Efficient inhibition of ovarian cancer growth and prolonged survival by transfection with a novel pro-apoptotic gene, hPNAS-4, in a mouse model. In vivo and in vitro results.
    Yang F, Li Z, Deng H, Yang H, Yan F, Qian Z, Chen L, Wei Y, Zhao X.
    Oncology; 2008 Sep 01; 75(3-4):137-44. PubMed ID: 18824876
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer.
    Hengstler JG, Lange J, Kett A, Dornhöfer N, Meinert R, Arand M, Knapstein PG, Becker R, Oesch F, Tanner B.
    Cancer Res; 1999 Jul 01; 59(13):3206-14. PubMed ID: 10397267
    [Abstract] [Full Text] [Related]

  • 35. Concurrent abnormal expression of erbB-2, myc and ras genes is associated with poor outcome of ovarian cancer patients.
    Katsaros D, Theillet C, Zola P, Louason G, Sanfilippo B, Isaia E, Arisio R, Giardina G, Sismondi P.
    Anticancer Res; 1995 Jul 01; 15(4):1501-10. PubMed ID: 7654038
    [Abstract] [Full Text] [Related]

  • 36. Ets-1 messenger RNA expression is a novel marker of poor survival in ovarian carcinoma.
    Davidson B, Reich R, Goldberg I, Gotlieb WH, Kopolovic J, Berner A, Ben-Baruch G, Bryne M, Nesland JM.
    Clin Cancer Res; 2001 Mar 01; 7(3):551-7. PubMed ID: 11297247
    [Abstract] [Full Text] [Related]

  • 37. Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition.
    Au-Yeung G, Lang F, Azar WJ, Mitchell C, Jarman KE, Lackovic K, Aziz D, Cullinane C, Pearson RB, Mileshkin L, Rischin D, Karst AM, Drapkin R, Etemadmoghadam D, Bowtell DD.
    Clin Cancer Res; 2017 Apr 01; 23(7):1862-1874. PubMed ID: 27663592
    [Abstract] [Full Text] [Related]

  • 38. High cyclin E1 protein, but not gene amplification, is prognostic for basal-like breast cancer.
    Aziz D, Lee C, Chin V, Fernandez KJ, Phan Z, kConFab InvestigatorsPeter MacCallum Cancer Centre, Victorian Comprehensive Cancer Centre, Parkville, VIC, Australia.Sir Peter MacCallum Cancer Centre, Department of Oncology, The University of Melbourne, Parkville, VIC, Australia., AOCS Study GroupPeter MacCallum Cancer Centre, Victorian Comprehensive Cancer Centre, Parkville, VIC, Australia., Waring P, Caldon CE.
    J Pathol Clin Res; 2022 Jul 01; 8(4):355-370. PubMed ID: 35384378
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.